Portal de investigación
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Roy-Vallejo, Emilia
- Sanchez Purificacion, Aquilino
- Torres Pena, Jose David
- Sanchez Moreno, Beatriz
- Arnalich, Francisco
- Garcia Blanco, Maria Jose
- Lopez Miranda, Jose
- Romero-Cabrera, Juan Luis
- Herrero Gil, Carmen Rosario
- Bascunana, Jose
- Rubio-Rivas, Manuel
- Pintos Otero, Sara
- Martinez Sempere, Veronica
- Ballano Rodriguez-Solis, Jesus
- Luque del Pino, Jairo
- Gonzalez Noya, Amara
- Navas-Alcantara, Maria Sierra
- Cortes Rodriguez, Begona
- Alcala, Jose Nicolas
- Suarez-Lombrana, Ana
- Andres Soler, Jorge
- Gomez-Huelgas, Ricardo
- Casas-Rojo, Jose Manuel
- Millan Nunez-Cortes, Jesus
Grupos
Abstract
Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality ( p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis ( p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63-0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62-0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.
Datos de la publicación
- ISSN/ISSNe:
- 2077-0383, 2077-0383
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.3390/jcm10122642
- PubMed:
- 34204014
- Factor de Impacto:
- 1,040 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Journal of Clinical Medicine MDPI
Citas Recibidas en Web of Science: 9
Documentos
- No hay documentos
Filiaciones
Keywords
- ACEI, ARB, COVID-19, MACE, prognosis
Campos de Estudio
Cita
Roy E,Sanchez A,Torres JD,Sanchez B,Arnalich F,Garcia MJ,Lopez J,Romero JL,Herrero CR,Bascunana J,Rubio M,Pintos S,Martinez V,Ballano Rodriguez J,GIL R,Luque del Pino J,Gonzalez A,Navas MS,Cortes B,Alcala JN,Suarez A,Andres J,Gomez R,Casas JM,Millan Nunez J. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. J. Clin. Med. 2021. 10. (12):2642. IF:4,964. (2).